Authorization and availability of the biological against Respiratory Syncytial Virus
The Secretary of Health of Mexico, David Kershenobich, confirmed during the presidential morning conference that the vaccine against Respiratory Syncytial Virus (RSV) will be available in the country in a very short period of time. This announcement represents a significant advance in the public health strategy to address seasonal respiratory infections. The federal official explained that the immunizer has already passed the critical regulatory process, receiving authorization from the Federal Commission for the Protection against Sanitary Risks (Cofepris). This regulatory body prioritized the evaluation of the drug, recognizing its urgency to protect the vulnerable population.
Kershenobich emphasized the clinical relevance of this biological, pointing out its double importance: as a protection tool for pregnant women and as a shield against potential outbreaks of respiratory disease that characterize the winter season. “We are in the process of acquiring it now,” he stated, indicating that the administrative and logistical procedures after approval are underway to guarantee its prompt distribution.
Target population and application strategy
Once the biological product reaches the national territory, the health authorities must define and precisely communicate the eligibility criteria and the priority groups for inoculation. The secretary clarified that it is necessary to establish under what specific clinical conditions this particular vaccine will be indicated. “We have constant monitoring of respiratory diseases and there will be a precise indication in due course,” he explained, stressing that the decision will be based on active epidemiological surveillance.
The risk groups initially identified are two. Firstly, the population of older adults who, due to their condition, may be more exposed to serious RSV infections. Secondly, the application is contemplated in pregnant women, with a specific administration window between weeks 32 and 36 of gestation. This strategy, known as maternal immunization, seeks to transfer protective antibodies to the newborn, providing it with defenses during its first months of life, when it is most susceptible to severe complications from this virus.
The arrival of this vaccine complements the national vaccination scheme and reinforces the capacity of the health system to mitigate the impact of RSV, a common pathogen that can lead to hospitalizations for bronchiolitis or pneumonia, especially in infants and the elderly. The secretary’s insistence that the product “will be available very soon” reflects the commitment to closing the access gap to high-impact medical innovations for the Mexican population.
Do you think this news is crucial for public health? Share this progress on your social networks to keep your community informed and explore more content on prevention and vaccination on our site.
